Medication info

Mirae Ibandronate Injection (Ibandronic Acid Sodium Hydrate)

Prescription medicationInjectionsIntravenous injectionExpired
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Mirae Biopharma Co., Ltd.
Appearance
This injection is a colorless, transparent solution contained in a colorless, transparent glass pre-filled syringe, accompanied by a single-use injection needle.
Packaging
3 milliliters / pre-filled syringe
Approval status
Expired

MFDS item code 202002603 · Notified 2020.04.13

This product's status changed to Expired on 2025.04.13. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from then on. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is at least 30ml/min. There is insufficient clinical experience in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min; therefore, use of this medicine is not recommended in these patients. Elderly patients No dose adjustment is necessary.
Child administration
Efficacy and safety in children 18 years of age or younger have not been studied.

Ingredients

Manufacturer
Mirae Biopharma Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used to treat osteoporosis that may occur in postmenopausal women. Osteoporosis is a disease that weakens bones, increasing the risk of fractures. This medicine helps increase bone strength and prevent fractures. With consistent use, it can improve bone health and reduce discomfort in daily life. Therefore, it is effective in treating osteoporosis resulting from decreased bone density after menopause.

How it is given

Adult administration

Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from then on. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is at least 30ml/min. There is insufficient clinical experience in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min; therefore, use of this medicine is not recommended in these patients. Elderly patients No dose adjustment is necessary.

Child administration

Efficacy and safety in children 18 years of age or younger have not been studied.

Precautions

This medication must be administered intravenously and great care should be taken to avoid causing tissue damage if administered intra-arterially or peri-venously. It should not be given to patients with hypersensitivity to this drug or untreated hypocalcemia. Administration may lead to gastrointestinal symptoms such as gastritis, diarrhea, abdominal pain, indigestion, nausea, and constipation, as well as musculoskeletal issues such as myalgia or arthralgia. Moreover, influenza-like symptoms such as fever, chills, fatigue, myalgia, and arthralgia may occur temporarily but are usually mild and resolve without treatment. This drug can temporarily lower serum calcium levels, so it should be administered after treatment in cases of hypocalcemia or bone and mineral metabolism disorders. Sufficient calcium and vitamin D intake are essential, and supplements should be taken if necessary. Patients undergoing dental treatment are at risk of jaw osteonecrosis, so it is advisable to check oral condition before administration and avoid excessive dental procedures during treatment. Patients receiving this medication can rarely experience osteonecrosis of the jaw or external auditory canal, so they should consult a doctor immediately if they have ear pain or discharge. Additionally, if there is dull pain in the thigh or groin area after drug administration, the possibility of atypical femoral fracture should be suspected and evaluated. This medication can cause acute renal failure or severe allergic reactions (anaphylaxis), so monitoring by healthcare professionals is necessary during administration, and administration should be discontinued immediately if adverse reactions occur. Safety for pregnant or nursing women has not been established, so avoidance is recommended. The safety and efficacy of this medication in children have not been confirmed, so it should not be used. Overdosage may affect kidney and liver function, requiring careful monitoring and appropriate treatment. This medication should not be mixed with solutions containing calcium or other intravenously administered drugs, and the syringe and needle should not be reused and must be disposed of safely.

Side effects

Gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reaction, phlebitis, thrombophlebitis, hypersensitivity reaction, angioedema, facial swelling, edema, urticaria, osteonecrosis of the jaw and external auditory canal, uveitis, scleral inflammation, episcleritis, anaphylactic reaction, shock, worsened asthma, Stevens-Johnson syndrome, erythema multiforme, bullous dermatitis, atypical femoral fracture and intertrochanteric fracture, dizziness, optic atrophy, lower motor neuron lesion, tremor, gastrointestinal disorders unspecified, benign gastrointestinal neoplasm, toothache, hyperventilation, cough, dyspnea, laryngitis, vulvitis, menopausal symptoms, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, skin desquamation, multiple organ failure, death, decreased sensation, acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1°C and 30°C. Proper storage will preserve the effectiveness and safety of the medication for a longer period.

Appearance and packaging

Appearance

This injection is a colorless, transparent solution contained in a colorless, transparent glass pre-filled syringe, accompanied by a single-use injection needle.

Package unit

3 milliliters / pre-filled syringe

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.